US 12139543
Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
granted A61KA61K39/39533A61K47/6817
Quick answer
US patent 12139543 (Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR) held by CytomX Therapeutics, Inc. expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K39/39533, A61K47/6817, A61K47/6849